News
LMDXW
--
0.00%
--
BRIEF-Lumiradx Receives WHO Emergency Use Listing For Sars-Cov-2 AG Test
reuters.com · 2d ago
LumiraDx Receives WHO Emergency Use Listing for SARS-CoV-2 Ag Test
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care diagnostics company, announced today that its rapid COVID-19 antigen assay, LumiraDx SARS-CoV-2 Ag Test has successfully received the Emergency Use Listing (EUL) by the World Health Organizat...
PR Newswire · 2d ago
BRIEF-LumiraDx Five-Minute SARS-CoV-2 Ag Ultra Test Achieves CE Marking
reuters.com · 3d ago
BRIEF-LumiraDx Reports First Quarter 2022 Results
reuters.com · 05/11 20:04
LumiraDx Reports First Quarter 2022 Results
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the first quarter ended March 31, 2022.
PR Newswire · 05/11 20:01
LumiraDx to Announce First Quarter Financial Results and Host Quarterly Conference Call on May 11
LumiraDx Limited (Nasdaq: LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its first quarter financial results on Wednesday, May 11, 2022. On the day of the release, LumiraDx will host a conference call and webcas...
PR Newswire · 04/29 12:02
BRIEF-LumiraDx Reports Fourth Quarter And Full Year 2021 Results
reuters.com · 03/10 11:06
LumiraDx Reports Fourth Quarter and Full Year 2021 Results
LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, today announced financial and operational results for the fourth quarter and full year ended December 31, 2021.
PR Newswire · 03/10 11:05
LumiraDx to Announce Fourth Quarter and Full Year 2021 Financial Results and Host Quarterly Conference Call on March 10
LumiraDx Limited (Nasdaq:LMDX), a next-generation point of care (POC) diagnostics company, announced it will release its fourth quarter and full year 2021 financial results on Thursday, March 10, 2022. On the day of the release, LumiraDx will host a confer...
PR Newswire · 03/03 14:03
LumiraDx Announces Pricing of $56.5 Million Convertible Notes Offering
LumiraDx Limited (Nasdaq: LMDX) announced today that it entered into privately negotiated subscription agreements with certain investors pursuant to which LumiraDx agreed to sell and the investors agreed to purchase from LumiraDx (the "notes offering") $56...
PR Newswire · 03/01 12:00
BRIEF-Lumiradx Receives UK MHRA Approval For Sars-Cov-2 RNA STAR Complete
reuters.com · 02/21 09:21
BRIEF-Lumiradx Lab Analysis Confirms Its Covid-19 Antigen Test Detects The Omicron Variant
reuters.com · 01/14 11:38
LumiraDx Lab Analysis Confirms its COVID-19 Antigen Test Detects the Omicron Variant
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced that results from ongoing testing and monitoring of COVID-19 variants show its SARS-CoV-2 Antigen test detects the Omicron Variant. In-house wet testing with live...
PR Newswire · 01/14 11:18
BRIEF-LumiraDx Has Commenced Shipments In Europe For Its Covid-19 & Flu A/B Microfluidic Antigen Test
reuters.com · 01/11 14:45
LumiraDx has Commenced Shipments in Europe for its COVID-19 & Flu A/B Microfluidic Antigen Test
LumiraDx (Nasdaq: LMDX), a next-generation point of care diagnostics company, today announced preliminary results for the fourth quarter of 2021 as well as expected full-year revenue.
PR Newswire · 01/11 14:02
BRIEF-Lumiradx CRP Test Achieves CE Marking
reuters.com · 01/11 11:35
BRIEF-LumiraDx Covid-19 & Flu A/B Rapid Antigen Test Achieves CE Marking
reuters.com · 12/23/2021 11:07
LumiraDx Fast Lab Solutions Partners with Audere for At-Home Self- Collection Solution for use with SARS-CoV-2 RNA STAR Complete
LumiraDx (Nasdaq: LMDX) today announced a partnership with digital health non-profit Audere, to offer a self-collected COVID-19 nasal specimen collection kit that has been authorized for use with the LumiraDx SARS-CoV-2 RNA STAR Complete assay to process s...
PR Newswire · 12/15/2021 13:17
How Much Of LumiraDx Limited (NASDAQ:LMDX) Do Insiders Own?
Every investor in LumiraDx Limited ( NASDAQ:LMDX ) should be aware of the most powerful shareholder groups. Large...
Simply Wall St. · 12/06/2021 11:37
BRIEF-FDA Reissues Lumiradx Fast Lab Solutions' Eua For Sars Cov-2 Rna Star Complete Molecular Reagents To Allow High Throughput And Asymptomatic Testing Solutions
reuters.com · 12/01/2021 13:29
Webull provides a variety of real-time LMDXW stock news. You can receive the latest news about Lumiradx Limited through multiple platforms. This information may help you make smarter investment decisions.
About LMDXW
LumiraDx Limited is a diagnostic company. The Company is focused on transforming community-based healthcare by providing critical diagnostic information to healthcare providers at the point of need. The Company has developed and launched LumiraDx Platform, a platform which is an integrated system comprised of a small, point of care (POC) instrument, microfluidic test strips, and secure digital connectivity. The Company has developed five diagnostic tests which includes SARS-CoV-2 antigen, SARS-CoV-2 antigen pool, SARS-CoV-2 antibody, International Normalized Ratio (INR) test, and D-Dimer test. It has also developed two rapid COVID-19 reagent testing kits for use on open molecular systems, LumiraDx SARS-CoV-2 RNA STAR and SARS-CoV-2 RNA STAR. Its platform has a pipeline of approximately more than 30 tests in various stages of development for the community-based healthcare settings.